Brind.
  1. A CTMSS Meeting took place in San Diego involving TMS.

AbCellera to Present Phase 1/2 Results for Vasomotor Symptom Drug at TMS Meeting

1 report, 1 independent Updated Thu 00:00
AI-generated briefing. Brind wrote this from the reports listed below. It can be wrong. Each section says how much you can rely on it, and the sources are linked so you can check.

What happened

Some supportReported by 1 outlet

AbCellera announced it will present Phase 1/2 trial results for ABCL635 at The Menopause Society’s 2026 Annual Meeting. The presentation will cover the safety, pharmacokinetics, pharmacodynamics, and preliminary efficacy of ABCL635, an NK3R monoclonal antibody antagonist designed to treat vasomotor symptoms due to menopause. The presentation is scheduled for October 22 in San Diego, California.

From owensoundsuntimes.com

Why it matters

Some supportBrind's analysis of the reports

ABCL635 is an investigational drug intended for the non-hormonal treatment of moderate-to-severe vasomotor symptoms. The presentation of Phase 1/2 results provides insight into the clinical progress and potential commercial viability of AbCellera's pipeline.

The event is part of The Menopause Society’s 2026 Annual Meeting, which is being held in San Diego, California.

From owensoundsuntimes.com

Who's involved

  • AbCelleraPresenting clinical trial results for ABCL635, an investigational antibody drug.
  • TMSHosting the 2026 Annual Meeting where the presentation will take place.

Keep exploring

Part of

A CTMSS Meeting took place in San Diego involving TMS. All 1 developments

The entities involved

Coverage

Newest first; wire copies grouped